{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:34:34Z","timestamp":1791340474423,"version":"4.3.1"},"reference-count":18,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"28","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2014,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Front-line treatment of peripheral T-cell lymphomas (PTCL) involves regimens such as cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and results in a 5-year overall survival (OS) rate of less than 50%. This phase I open-label study evaluated the safety and activity of brentuximab vedotin administered sequentially with CHOP or in combination with CHP (CHOP without vincristine) as front-line treatment in patients with CD30\n                      <jats:sup>+<\/jats:sup>\n                      PTCL.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Patients received sequential treatment (once every 3 weeks) with brentuximab vedotin 1.8 mg\/kg (two cycles) followed by CHOP (six cycles) or brentuximab vedotin 1.8 mg\/kg plus CHP (BV+CHP) for six cycles (once every 3 weeks). Responders received single-agent brentuximab vedotin for eight to 10 additional cycles (for a total of 16 cycles). The primary objective was assessment of safety; secondary end points included objective response rate, complete remission (CR) rate, progression-free survival rate (PFS), and OS. There were no prespecified comparisons of the two treatment approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After sequential treatment, 11 (85%) of 13 patients achieved an objective response (CR rate, 62%; estimated 1-year PFS rate, 77%). Grade 3\/4 adverse events occurred in eight (62%) of 13 patients. At the end of combination treatment, all patients (n = 26) achieved an objective response (CR rate, 88%; estimated 1-year PFS rate, 71%). All seven patients without anaplastic large-cell lymphoma achieved CR. Grade 3\/4 adverse events (\u2265 10%) in the combination-treatment group were febrile neutropenia (31%), neutropenia (23%), anemia (15%), and pulmonary embolism (12%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Brentuximab vedotin, administered sequentially with CHOP or in combination with CHP, had a manageable safety profile and exhibited substantial antitumor activity in newly diagnosed patients with CD30\n                      <jats:sup>+<\/jats:sup>\n                      PTCL. A randomized phase III trial is under way, comparing BV+CHP with CHOP (clinical trial No. NCT01777152).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.2013.54.2456","type":"journal-article","created":{"date-parts":[[2014,8,19]],"date-time":"2014-08-19T02:18:17Z","timestamp":1408414697000},"page":"3137-3143","source":"Crossref","is-referenced-by-count":169,"title":["Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30\n                    <sup>+<\/sup>\n                    Peripheral T-Cell Lymphomas: Results of a Phase I Study"],"prefix":"10.1200","volume":"32","author":[{"given":"Michelle A.","family":"Fanale","sequence":"first","affiliation":[{"name":"Michelle A. Fanale, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven M. Horwitz, Memorial Sloan-Kettering Cancer Center, New York, NY; Andres Forero-Torres, University of Alabama at Birmingham, Birmingham, AL; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Ranjana H. Advani, Stanford University Medical Center, Palo Alto; Robert W. Chen, City of Hope National Medical Center, Duarte, CA; Barbara Pro, Fox Chase Cancer Center, Philadelphia, PA; Dirk Huebner,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Horwitz","sequence":"additional","affiliation":[{"name":"Michelle A. Fanale, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven M. Horwitz, Memorial Sloan-Kettering Cancer Center, New York, NY; Andres Forero-Torres, University of Alabama at Birmingham, Birmingham, AL; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Ranjana H. Advani, Stanford University Medical Center, Palo Alto; Robert W. Chen, City of Hope National Medical Center, Duarte, CA; Barbara Pro, Fox Chase Cancer Center, Philadelphia, PA; Dirk Huebner,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Forero-Torres","sequence":"additional","affiliation":[{"name":"Michelle A. Fanale, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven M. Horwitz, Memorial Sloan-Kettering Cancer Center, New York, NY; Andres Forero-Torres, University of Alabama at Birmingham, Birmingham, AL; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Ranjana H. Advani, Stanford University Medical Center, Palo Alto; Robert W. Chen, City of Hope National Medical Center, Duarte, CA; Barbara Pro, Fox Chase Cancer Center, Philadelphia, PA; Dirk Huebner,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[{"name":"Michelle A. Fanale, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven M. Horwitz, Memorial Sloan-Kettering Cancer Center, New York, NY; Andres Forero-Torres, University of Alabama at Birmingham, Birmingham, AL; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Ranjana H. Advani, Stanford University Medical Center, Palo Alto; Robert W. Chen, City of Hope National Medical Center, Duarte, CA; Barbara Pro, Fox Chase Cancer Center, Philadelphia, PA; Dirk Huebner,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana H.","family":"Advani","sequence":"additional","affiliation":[{"name":"Michelle A. Fanale, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven M. Horwitz, Memorial Sloan-Kettering Cancer Center, New York, NY; Andres Forero-Torres, University of Alabama at Birmingham, Birmingham, AL; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Ranjana H. Advani, Stanford University Medical Center, Palo Alto; Robert W. Chen, City of Hope National Medical Center, Duarte, CA; Barbara Pro, Fox Chase Cancer Center, Philadelphia, PA; Dirk Huebner,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pro","sequence":"additional","affiliation":[{"name":"Michelle A. Fanale, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven M. Horwitz, Memorial Sloan-Kettering Cancer Center, New York, NY; Andres Forero-Torres, University of Alabama at Birmingham, Birmingham, AL; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Ranjana H. Advani, Stanford University Medical Center, Palo Alto; Robert W. Chen, City of Hope National Medical Center, Duarte, CA; Barbara Pro, Fox Chase Cancer Center, Philadelphia, PA; Dirk Huebner,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Chen","sequence":"additional","affiliation":[{"name":"Michelle A. Fanale, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven M. Horwitz, Memorial Sloan-Kettering Cancer Center, New York, NY; Andres Forero-Torres, University of Alabama at Birmingham, Birmingham, AL; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Ranjana H. Advani, Stanford University Medical Center, Palo Alto; Robert W. Chen, City of Hope National Medical Center, Duarte, CA; Barbara Pro, Fox Chase Cancer Center, Philadelphia, PA; Dirk Huebner,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Davies","sequence":"additional","affiliation":[{"name":"Michelle A. Fanale, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven M. Horwitz, Memorial Sloan-Kettering Cancer Center, New York, NY; Andres Forero-Torres, University of Alabama at Birmingham, Birmingham, AL; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Ranjana H. Advani, Stanford University Medical Center, Palo Alto; Robert W. Chen, City of Hope National Medical Center, Duarte, CA; Barbara Pro, Fox Chase Cancer Center, Philadelphia, PA; Dirk Huebner,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Illidge","sequence":"additional","affiliation":[{"name":"Michelle A. Fanale, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven M. Horwitz, Memorial Sloan-Kettering Cancer Center, New York, NY; Andres Forero-Torres, University of Alabama at Birmingham, Birmingham, AL; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Ranjana H. Advani, Stanford University Medical Center, Palo Alto; Robert W. Chen, City of Hope National Medical Center, Duarte, CA; Barbara Pro, Fox Chase Cancer Center, Philadelphia, PA; Dirk Huebner,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Huebner","sequence":"additional","affiliation":[{"name":"Michelle A. Fanale, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven M. Horwitz, Memorial Sloan-Kettering Cancer Center, New York, NY; Andres Forero-Torres, University of Alabama at Birmingham, Birmingham, AL; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Ranjana H. Advani, Stanford University Medical Center, Palo Alto; Robert W. Chen, City of Hope National Medical Center, Duarte, CA; Barbara Pro, Fox Chase Cancer Center, Philadelphia, PA; Dirk Huebner,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana A.","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Michelle A. Fanale, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven M. Horwitz, Memorial Sloan-Kettering Cancer Center, New York, NY; Andres Forero-Torres, University of Alabama at Birmingham, Birmingham, AL; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Ranjana H. Advani, Stanford University Medical Center, Palo Alto; Robert W. Chen, City of Hope National Medical Center, Duarte, CA; Barbara Pro, Fox Chase Cancer Center, Philadelphia, PA; Dirk Huebner,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei R.","family":"Shustov","sequence":"additional","affiliation":[{"name":"Michelle A. Fanale, The University of Texas MD Anderson Cancer Center, Houston, TX; Steven M. Horwitz, Memorial Sloan-Kettering Cancer Center, New York, NY; Andres Forero-Torres, University of Alabama at Birmingham, Birmingham, AL; Nancy L. Bartlett, Washington University School of Medicine, St Louis, MO; Ranjana H. Advani, Stanford University Medical Center, Palo Alto; Robert W. Chen, City of Hope National Medical Center, Duarte, CA; Barbara Pro, Fox Chase Cancer Center, Philadelphia, PA; Dirk Huebner,..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","first-page":"269","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues (ed 4)","author":"Swerdlow SH","year":"2008"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-134270"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh392"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08329.x"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"B7","volume-title":"Presented at the Am Soc Hematol Annual Meeting","author":"Pro B"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-074641"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq635"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.2719"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn022"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.4870"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.00856.x"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404306"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-312603"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2013.54.2456","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T18:43:42Z","timestamp":1653504222000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2013.54.2456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,1]]},"references-count":18,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2014,10,1]]}},"alternative-id":["10.1200\/JCO.2013.54.2456"],"URL":"https:\/\/doi.org\/10.1200\/jco.2013.54.2456","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,1]]}}}